From:  Comparison of weekly docetaxel regimens in prostate cancer: a systematic review and frequentist network meta-analysis

 League tables presenting the pairwise meta-analysis (upper-right half of the table) and the network meta-analysis (lower-left half of the table) differences among docetaxel doses in prostate cancer for all outcomes.

OutcomeTreatment comparison
PSA response rateBiweekly1.13 (0.82; 1.57)0.79 (0.37; 1.70)
1.08 (0.79; 1.49)Triweekly0.76 (0.48; 1.19)
0.86 (0.53; 1.41)0.79 (0.52; 1.22)Weekly
Time for treatment failure or progression*Biweekly–2.42 (–4.65; –0.19)3.20 (–1.15; 7.55)
–2.42 (–4.65; –0.19)Triweekly18.80 (13.79; 23.81)
8.49 (4.65; 12.33)10.91 (6.94; 14.87)Weekly
HepatotoxicityBiweekly1.21 (0.58; 2.54)2.78 (0.81; 9.51)
1.15 (0.56; 2.38)Triweekly3.21 (1.50; 6.89)
3.71 (1.41; 9.73)3.21 (1.50; 6.89)Weekly
VomitingBiweekly0.51 (0.29; 0.89)NA
0.51 (0.29; 0.89)Triweekly2.47 (1.31; 4.63)
1.25 (0.54; 2.90)2.47 (1.31; 4.63)Weekly
Any adverse eventsBiweekly1.09 (0.99; 1.21)0.88 (0.58; 1.35)
1.09 (0.99; 1.21)Triweekly0.78 (0.54; 1.14)
0.87 (0.61; 1.23)0.79 (0.56; 1.12)Weekly
ThrombocytopeniaBiweekly1.07 (0.36; 3.15)NA
1.07 (0.36; 3.15)Triweekly0.85 (0.19; 3.79)
0.90 (0.14; 5.74)0.85 (0.19; 3.79)Weekly
AnemiaBiweekly0.78 (0.53; 1.16)NA
0.78 (0.53; 1.16)Triweekly0.88 (0.36; 2.18)
0.69 (0.26; 1.85)0.88 (0.36; 2.18)Weekly
ArthralgiaBiweekly1.07 (0.56; 2.07)NA
1.07 (0.56; 2.07)Triweekly1.06 (0.41; 2.71)
1.14 (0.36; 3.57)1.06 (0.41; 2.71)Weekly
NeuropathyBiweekly1.07 (0.51; 2.27)0.31 (0.01; 8.34)
1.04 (0.49; 2.19)Triweekly1.40 (0.33; 5.97)
1.31 (0.28; 6.22)1.26 (0.31; 5.18)Weekly
NeutropeniaBiweekly1.52 (0.54; 4.26)NA
1.52 (0.54; 4.26)Triweekly1.24 (0.22; 7.16)
1.88 (0.25; 14.40)1.24 (0.22; 7.16)Weekly
FatigueBiweekly0.85 (0.47; 1.53)1.30 (0.26; 6.52)
0.82 (0.46; 1.45)Triweekly1.66 (0.68; 4.05)
1.46 (0.55; 3.87)1.79 (0.76; 4.22)Weekly
Febrile neutropeniaBiweekly0.38 (0.12; 1.18)NA
0.38 (0.12; 1.18)Triweekly12.31 (1.32; 114.50)
4.72 (0.39; 57.34)12.31 (1.32; 114.50)Weekly
NauseaBiweekly0.46 (0.24; 0.92)NA
0.46 (0.24; 0.92)Triweekly2.47 (0.90; 6.79)
1.14 (0.34; 3.88)2.47 (0.90; 6.79)Weekly
DiarrheaBiweekly0.74 (0.37; 1.48)NA
0.74 (0.37; 1.48)Triweekly1.27 (0.27; 6.01)
0.94 (0.17; 5.15)1.27 (0.27; 6.01)Weekly
Anorexia**NA
Return to article view

*: Mean difference (MD); all other outcomes report risk ratio (RR). **: No network estimate due to a single comparison of triweekly vs. biweekly therapy. NA represents that there is no direct evidence available for that specific comparison. Note: effect estimates (RR or MD) with 95% confidence intervals from the NMA are located at the intersection of each row- and column-defining intervention. In the lower-left half of the table, an RR < 1 (or MD < 0) favors the row-defining treatment, while in the upper-right half, an OR < 1 (or MD < 0) favors the column-defining treatment, with statistically significant results presented in bold. NMA: network meta-analysis.